Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RMC-5552 |
Synonyms | |
Therapy Description |
RMC-5552 selectively inhibits mTORC1, resulting in decreased downstream signaling and potentially leading to reduced growth and increased apoptosis in tumor cells (European Journal of Cancer 138 (2020): S1-S62). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RMC-5552 | RMC5552|RMC 5552 | mTORC1 Inhibitor 9 | RMC-5552 selectively inhibits mTORC1, resulting in decreased downstream signaling and potentially leading to reduced growth and increased apoptosis in tumor cells (European Journal of Cancer 138 (2020): S1-S62). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN inact mut | head and neck cancer | predicted - sensitive | RMC-5552 | Case Reports/Case Series | Actionable | In a Phase I/Ib trial, RMC-5552 treatment resulted in an objective response rate of 20% (1/5) and 3 stable disease in patients with advanced solid tumors, with 1 partial response observed in a patient with head and neck cancer harboring a pathogenic PTEN mutation (J of Clin Oncol40, no. 16_suppl (June 01, 2022) 3098; NCT04774952). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05557292 | Phase I | RMC-5552 | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT04774952 | Phase I | RMC-5552 | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors | Active, not recruiting | USA | 0 |